Citius Pharmaceuticals, Inc. 8K

Citius Pharmaceuticals, Inc. reported fiscal Q3 2026 results showing growing LYMPHIR commercialization, positive early clinical data, additional financings and term loan draw, and a continued net loss alongside an expansion of Citius Oncology’s board.

On August 14, 2026, Citius Pharmaceuticals, Inc. reported its fiscal third quarter 2026 financial results and provided a business update highlighting continued commercial momentum for its oncology product LYMPHIR, including $1.5 million in quarterly revenue and $7.1 million for the first nine months of fiscal 2026, near-universal payer coverage, and expanded commercial and medical affairs teams deployed nationwide through EVERSANA. The company outlined positive Phase 1 clinical data for LYMPHIR in combination with pembrolizumab in recurrent or refractory gynecologic malignancies and as a pre-CAR-T therapy in high-risk relapsed or refractory DLBCL, suggesting potential expansion beyond cutaneous T-cell lymphoma. Citius also disclosed financing actions, including a $4.5 million registered direct offering completed in April 2026, $9.7 million in net proceeds from warrant exercises, and drawing $10.0 million under the first tranche of a Citius Oncology senior secured term loan facility of up to $25.0 million, while ending June 30, 2026 with $17.0 million in cash and cash equivalents. The company reported a net loss applicable to common stockholders of $8.9 million for the quarter and $38.3 million year-to-date, driven in part by a non-recurring $19.7 million contract cancellation charge and increased commercialization spending, and announced the appointment of Jonathan Peri, Ph.D., J.D., as an independent director of Citius Oncology effective August 10, 2026.

Filing Facts

CIK

1506251

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-090181

Alert Tier

6